SG169366A1 - Pharmaceutical composition of microspheres for preventing diabetic foot amputation - Google Patents

Pharmaceutical composition of microspheres for preventing diabetic foot amputation

Info

Publication number
SG169366A1
SG169366A1 SG201100715-0A SG2011007150A SG169366A1 SG 169366 A1 SG169366 A1 SG 169366A1 SG 2011007150 A SG2011007150 A SG 2011007150A SG 169366 A1 SG169366 A1 SG 169366A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
microspheres
diabetic foot
preventing diabetic
foot amputation
Prior art date
Application number
SG201100715-0A
Other languages
English (en)
Inventor
Saez Mart
Original Assignee
Ct De Ingenier A Genetica Y
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38185604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG169366(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Ingenier A Genetica Y filed Critical Ct De Ingenier A Genetica Y
Publication of SG169366A1 publication Critical patent/SG169366A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1808Epidermal growth factor [EGF] urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG201100715-0A 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation SG169366A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Publications (1)

Publication Number Publication Date
SG169366A1 true SG169366A1 (en) 2011-03-30

Family

ID=38185604

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201100715-0A SG169366A1 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation

Country Status (24)

Country Link
US (1) US8741848B2 (es)
EP (1) EP1987817B1 (es)
JP (1) JP5219841B2 (es)
KR (1) KR101401273B1 (es)
CN (2) CN101400338A (es)
AR (1) AR059234A1 (es)
AT (1) ATE437631T1 (es)
AU (1) AU2007211753B2 (es)
BR (1) BRPI0707395A2 (es)
CA (1) CA2640743C (es)
CU (1) CU23388B6 (es)
CY (1) CY1109513T1 (es)
DE (1) DE602007001786D1 (es)
DK (1) DK1987817T3 (es)
ES (1) ES2330688T3 (es)
HK (1) HK1198743A1 (es)
MY (1) MY143742A (es)
PL (1) PL1987817T3 (es)
PT (1) PT1987817E (es)
RU (1) RU2426528C2 (es)
SG (1) SG169366A1 (es)
SI (1) SI1987817T1 (es)
WO (1) WO2007087759A2 (es)
ZA (1) ZA200806648B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 PHA-mPEG 공중합 나노 컨테이너
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN106267163A (zh) * 2015-06-09 2017-01-04 济南博创医药科技有限公司 一种治疗皮肤创伤的药物组合物及其药物制剂
MX2016016339A (es) * 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
KR102218427B1 (ko) * 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
AU633078B2 (en) 1989-04-04 1993-01-21 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JPH04501123A (ja) 1989-08-01 1992-02-27 ザ ユニヴァーシティ オブ ミシガン 脱水/水補給リポソームに被嚢されたペプチド/タンパク質の局所送達
AU629316B2 (en) 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO1997041899A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
ATE537845T1 (de) * 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
WO2003075949A1 (en) 2002-03-12 2003-09-18 Bio-Click Technologies Ltd. Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) * 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23411B6 (es) 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético

Also Published As

Publication number Publication date
CU23388B6 (es) 2009-07-16
CA2640743A1 (en) 2007-08-09
PT1987817E (pt) 2009-10-26
MY143742A (en) 2011-07-15
PL1987817T3 (pl) 2010-01-29
WO2007087759A2 (es) 2007-08-09
SI1987817T1 (sl) 2009-12-31
HK1198743A1 (en) 2015-06-05
RU2426528C2 (ru) 2011-08-20
WO2007087759A3 (es) 2007-09-20
EP1987817B1 (en) 2009-07-29
BRPI0707395A2 (pt) 2011-05-03
CA2640743C (en) 2012-05-15
CN101400338A (zh) 2009-04-01
US8741848B2 (en) 2014-06-03
JP2009525288A (ja) 2009-07-09
AU2007211753A1 (en) 2007-08-09
DE602007001786D1 (de) 2009-09-10
ZA200806648B (en) 2009-05-27
AR059234A1 (es) 2008-03-19
CY1109513T1 (el) 2014-08-13
ES2330688T3 (es) 2009-12-14
EP1987817A2 (en) 2008-11-05
KR101401273B1 (ko) 2014-05-29
ATE437631T1 (de) 2009-08-15
RU2008135354A (ru) 2010-03-10
AU2007211753B2 (en) 2012-03-01
JP5219841B2 (ja) 2013-06-26
CN103933552A (zh) 2014-07-23
KR20080096804A (ko) 2008-11-03
US20090220608A1 (en) 2009-09-03
DK1987817T3 (da) 2009-11-30

Similar Documents

Publication Publication Date Title
SG169366A1 (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
RU2013140182A (ru) Композиция гиалуроновой кислоты
UA80813C2 (en) Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
NZ596041A (en) Use of guanethidine for treating hypertension by local vascular delivery
WO2007098479A3 (en) Localized insulin delivery for bone healing
EP2422798A3 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
ATE406928T1 (de) Subkutane infusionsvorrichtung
IN266817B (es)
WO2009091549A8 (en) Modified starch material of biocompatible hemostasis
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
Orcajo et al. The use of plasma rich in growth factors (PRGF-Endoret) in the treatment of a severe mal perforant ulcer in the foot of a person with diabetes
WO2012020412A3 (en) Fibrin based scaffold, preparation and use thereof
WO2012018545A3 (en) Systems and methods for treatment of sleep apnea
WO2009016629A3 (en) Pharmaceutical composition for treating wounds and related methods
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
WO2009134054A3 (en) Heparin-conjugated fibrin gel and method and kit for preparing the same
HK1136492A1 (en) Agent for promoting healing of living body
DE60111637D1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
CN207871271U (zh) 一种医用硅酮凝胶疤痕贴
ATE301452T1 (de) Verfahren zur herstellung einer flüssigen dosierungseinheit und kit
CN201591866U (zh) 胰岛素腹部注射轮换卡
MY137139A (en) Formation of tissue engineered human skin using hpd as biomaterials
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences